Burundi confirms 171 mpox cases

Health officials report 171 mpox cases, with 137 active and no deaths; isolation wards being prepared


AFP August 22, 2024
Health workers inside a ward at the Kamenge University Hospital's Mpox treatment center in Bujumbura on August 22, 2024. PHOTO: AFP

Listen to article
NAIROBI:

Burundi has confirmed 171 cases of mpox, the health ministry said on Thursday, following confirmation of the first cases in the country last month.

Formerly known as monkeypox, mpox is an infectious disease caused by a virus transmitted to humans by infected animals that can also be passed from human to human through close physical contact.

"We already had a cumulative of 171 confirmed positive cases, 137 of which are still active," health ministry spokesman Polycarpe Ndayikeza told AFP.

"So far there have been no deaths from mpox in Burundi," he added.

Three cases of mpox were detected in Burundi in late July, with the health ministry reporting 153 confirmed cases on August 18.

Read also: Thailand reports mpox case in European traveller from Africa

"The epidemic continues to gain ground," the ministry said last month, adding it was in the process of creating isolation wards in district hospitals to care for mpox patients.

An official told AFP the cases detected appeared to be the "new variant" spreading in the neighbouring Democratic Republic of Congo.

While mpox has been known for decades, a new more deadly and more transmissible strain -- known as Clade 1b -- has driven the recent surge in cases.

Clade 1b causes death in about 3.6 per cent of cases, with children more at risk, according to the World Health Organization, which has declared an international health emergency over the latest outbreak.

Cases are surging in the region with outbreaks reported in the DRC, Kenya, Rwanda and Uganda, but have also been detected in Asia and Europe.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ